Intech Investment Management LLC Invests $300,000 in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Intech Investment Management LLC acquired a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 5,100 shares of the company’s stock, valued at approximately $300,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Driehaus Capital Management LLC lifted its stake in shares of Apogee Therapeutics by 2.6% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock valued at $83,338,000 after acquiring an additional 54,107 shares during the last quarter. Perceptive Advisors LLC lifted its stake in shares of Apogee Therapeutics by 2.2% in the 2nd quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock valued at $82,857,000 after acquiring an additional 45,241 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in shares of Apogee Therapeutics by 41.2% in the 2nd quarter. Affinity Asset Advisors LLC now owns 836,283 shares of the company’s stock valued at $32,908,000 after acquiring an additional 244,190 shares during the last quarter. Waypoint Capital Advisors LLC bought a new stake in shares of Apogee Therapeutics in the 3rd quarter valued at about $36,835,000. Finally, Victory Capital Management Inc. lifted its stake in shares of Apogee Therapeutics by 121.6% in the 3rd quarter. Victory Capital Management Inc. now owns 346,358 shares of the company’s stock valued at $20,345,000 after acquiring an additional 190,092 shares during the last quarter. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Stock Performance

Shares of NASDAQ:APGE opened at $52.02 on Thursday. Apogee Therapeutics, Inc. has a 52-week low of $18.84 and a 52-week high of $72.29. The firm has a market capitalization of $2.34 billion, a P/E ratio of -21.50 and a beta of 2.30. The stock has a 50 day moving average price of $52.90 and a 200-day moving average price of $48.30.

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 6,665 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $59.12, for a total transaction of $394,034.80. Following the sale, the insider now directly owns 267,463 shares in the company, valued at approximately $15,812,412.56. This trade represents a 2.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael Thomas Henderson sold 40,000 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $56.23, for a total value of $2,249,200.00. Following the sale, the chief executive officer now owns 1,354,487 shares in the company, valued at approximately $76,162,804.01. This represents a 2.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,330 shares of company stock valued at $3,906,508. Corporate insiders own 36.10% of the company’s stock.

Analysts Set New Price Targets

APGE has been the subject of a number of recent research reports. Wedbush boosted their target price on Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target for the company. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target for the company. Finally, Guggenheim reaffirmed a “buy” rating and set a $110.00 price target (up previously from $95.00) on shares of Apogee Therapeutics in a research report on Tuesday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $83.88.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.